Pacific Biosciences of California (PACB) Projected to Post Quarterly Earnings on Thursday

Pacific Biosciences of California (NASDAQ:PACB - Get Free Report) will likely be announcing its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect Pacific Biosciences of California to post earnings of ($0.19) per share and revenue of $36.90 million for the quarter.

Pacific Biosciences of California (NASDAQ:PACB - Get Free Report) last posted its earnings results on Thursday, February 13th. The biotechnology company reported ($0.20) earnings per share for the quarter, meeting the consensus estimate of ($0.20). The company had revenue of $39.22 million during the quarter, compared to analysts' expectations of $39.20 million. Pacific Biosciences of California had a negative net margin of 200.40% and a negative return on equity of 42.89%. During the same period last year, the company posted ($0.27) earnings per share. On average, analysts expect Pacific Biosciences of California to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Pacific Biosciences of California Price Performance

PACB stock traded up $0.02 during mid-day trading on Friday, hitting $1.13. The company had a trading volume of 5,908,510 shares, compared to its average volume of 9,697,027. The company has a 50-day moving average price of $1.26 and a 200 day moving average price of $1.66. Pacific Biosciences of California has a 12-month low of $1.06 and a 12-month high of $2.72. The company has a market capitalization of $339.05 million, a price-to-earnings ratio of -0.69 and a beta of 2.04. The company has a quick ratio of 8.64, a current ratio of 9.74 and a debt-to-equity ratio of 1.97.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. StockNews.com raised Pacific Biosciences of California to a "sell" rating in a research note on Tuesday, February 25th. Scotiabank cut their target price on shares of Pacific Biosciences of California from $6.00 to $2.00 and set a "sector outperform" rating for the company in a report on Tuesday, March 25th. Stephens reaffirmed an "overweight" rating and set a $2.50 price target on shares of Pacific Biosciences of California in a research note on Friday, February 14th. The Goldman Sachs Group dropped their price objective on shares of Pacific Biosciences of California from $1.75 to $1.50 and set a "neutral" rating for the company in a research note on Tuesday, February 18th. Finally, Canaccord Genuity Group restated a "buy" rating and set a $3.00 target price on shares of Pacific Biosciences of California in a research report on Thursday, April 10th. One analyst has rated the stock with a sell rating, five have given a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, Pacific Biosciences of California presently has an average rating of "Hold" and a consensus target price of $2.45.

Insider Buying and Selling

In other Pacific Biosciences of California news, insider Michele Farmer sold 24,349 shares of the firm's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $1.88, for a total value of $45,776.12. Following the completion of the sale, the insider now owns 187,592 shares of the company's stock, valued at $352,672.96. This trade represents a 11.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 2.40% of the stock is owned by corporate insiders.

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.